1440 - PD-L1 testing for access to pembrolizumab in treatment na´ve patients with locally advanced or metastatic non-small cell lung cancer

Page last updated: 16 February 2018

Application Detail



Description of Medical Service

ImmunoHistoChemistry test for evaluation of Programmed Cell Death Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab

Description of Medical Condition

Locally advanced or metastatic non-small cell lung cancer

Reason for Application

New MBS item

Medical Service Type


Previous Application Number

Not Applicable

Associated Documentation

Application Form


PICO Confirmation

Final Protocol (PDF 522 KB)
Final Protocol (Word 692 KB)

Assessment Report


Public Summary Document

Public Summary Document (PDF 240 KB)
Public Summary Document (Word 98 KB)

Meetings for this Application


11 - 12 August 2016


7 - 8 February 2017


6 - 7 April 2017